A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study will evaluate the efficacy and safety of orforglipron in participants withoverweight and assess whether it helps reduce the future risk of obesity‐relatedconditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression toclass 1 obesity.
Epistemonikos ID: fafafcb7b88b8c62f2adc0fa3782faf59f96dd4f
First added on: Sep 01, 2026